Document Detail


Internalization of oncolytic reovirus by human dendritic cell carriers protects the virus from neutralization.
MedLine Citation:
PMID:  21389099     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: Dendritic cells (DC) may be the most effective way of delivering oncolytic viruses to patients. Reovirus, a naturally occurring oncolytic virus, is currently undergoing early clinical trials; however, intravenous delivery of the virus is hampered by pre-existing antiviral immunity. Systemic delivery via cell carriage is a novel approach currently under investigation and initial studies have indicated its feasibility by using a variety of cell types and viruses. This study addressed the efficacy of human DC to transport virus in the presence of human neutralizing serum.
EXPERIMENTAL DESIGN: Following reovirus-loading, DC or T cells were cocultured with melanoma cells with or without neutralizing serum; the melanoma cells were then analyzed for cell death. Following reovirus loading, cells were examined by electron microscopy to identify mechanisms of delivery. The phagocytic function of reovirus-loaded DC was investigated by using labeled tumor cells and the ability of reovirus-loaded DC to prime T cells was also investigated.
RESULTS: In the presence of human neutralizing serum DC, but not T cells, were able to deliver reovirus for melanoma cell killing in vitro. Electron microscopy suggested that DC protected the virus by internalization, whereas with T cells it remained bound to the surface and hence accessible to neutralizing antibodies. Furthermore, DC loaded with reovirus were fully functional with regard to phagocytosis and priming of specific antitumor immune responses.
CONCLUSIONS: The delivery of reovirus via DC could be a promising new approach offering the possibility of combining systemic viral therapy for metastatic disease with induction of an antitumor immune response.
Authors:
Elizabeth J Ilett; Montserrat Bárcena; Fiona Errington-Mais; Stephen Griffin; Kevin J Harrington; Hardev S Pandha; Matthew Coffey; Peter J Selby; Ronald W A L Limpens; Mieke Mommaas; Rob C Hoeben; Richard G Vile; Alan A Melcher
Related Documents :
16211279 - E1b-deleted adenovirus replicates in p53-deficient lung cancer cells due to the absence...
17457979 - Kn-93, a specific inhibitor of camkii inhibits human hepatic stellate cell proliferatio...
11071849 - Overexpression of dan causes a growth suppression in p53-deficient saos-2 cells.
10455409 - Increase of bcnu sensitivity by wt-p53 gene therapy in glioblastoma lines depends on th...
20371709 - Sirt inhibitors induce cell death and p53 acetylation through targeting both sirt1 and ...
1984409 - Correlation of metabolic stability and altered quaternary structure of oncoprotein p53 ...
20099979 - X-irradiation of human bronchial cancer cells causes the bystander effects in normal br...
19532959 - Fluorescence-activated droplet sorting (fads): efficient microfluidic cell sorting base...
15312689 - Nutritional deficiency affects cell cycle status and viability in a549 cells: role of p...
Publication Detail:
Type:  Evaluation Studies; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't     Date:  2011-03-09
Journal Detail:
Title:  Clinical cancer research : an official journal of the American Association for Cancer Research     Volume:  17     ISSN:  1078-0432     ISO Abbreviation:  Clin. Cancer Res.     Publication Date:  2011 May 
Date Detail:
Created Date:  2011-05-03     Completed Date:  2011-09-15     Revised Date:  2014-09-13    
Medline Journal Info:
Nlm Unique ID:  9502500     Medline TA:  Clin Cancer Res     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2767-76     Citation Subset:  IM    
Copyright Information:
©2011 AACR.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antibodies, Neutralizing / adverse effects*
Cell Line, Tumor
Cytotoxicity, Immunologic / physiology
Dendritic Cells / immunology,  metabolism,  physiology,  virology*
Drug Carriers
Endocytosis / physiology
Humans
Melanoma / pathology,  therapy
Oncolytic Virotherapy* / methods
Oncolytic Viruses / metabolism*,  physiology
Reoviridae / metabolism,  physiology*
Skin Neoplasms / pathology,  therapy
T-Lymphocytes / immunology,  virology
Treatment Outcome
Viral Load / physiology
Virus Internalization*
Grant Support
ID/Acronym/Agency:
A5922//Cancer Research UK; CA RO1107082-02/CA/NCI NIH HHS; R01 CA107082/CA/NCI NIH HHS; R01 CA130878/CA/NCI NIH HHS; R01130878//PHS HHS; //Cancer Research UK
Chemical
Reg. No./Substance:
0/Antibodies, Neutralizing; 0/Drug Carriers
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Combined promoter methylation analysis of CADM1 and MAL: an objective triage tool for high-risk huma...
Next Document:  MK-1775, a potent Wee1 inhibitor, synergizes with gemcitabine to achieve tumor regressions, selectiv...